Well Lead Med Co Ltd (603309) - Net Assets
Based on the latest financial reports, Well Lead Med Co Ltd (603309) has net assets worth CN¥1.79 Billion CNY (≈ $262.05 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.73 Billion ≈ $398.78 Million USD) and total liabilities (CN¥934.35 Million ≈ $136.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Well Lead Med Co Ltd (603309) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.79 Billion |
| % of Total Assets | 65.71% |
| Annual Growth Rate | 17.16% |
| 5-Year Change | 11.63% |
| 10-Year Change | 105.78% |
| Growth Volatility | 27.61 |
Well Lead Med Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Well Lead Med Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Well Lead Med Co Ltd.
Annual Net Assets for Well Lead Med Co Ltd (2011–2025)
The table below shows the annual net assets of Well Lead Med Co Ltd from 2011 to 2025. Also explore Well Lead Med Co Ltd (603309) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.78 Billion ≈ $259.96 Million |
-6.65% |
| 2024-12-31 | CN¥1.90 Billion ≈ $278.48 Million |
+3.60% |
| 2023-12-31 | CN¥1.84 Billion ≈ $268.80 Million |
+5.58% |
| 2022-12-31 | CN¥1.74 Billion ≈ $254.58 Million |
+9.32% |
| 2021-12-31 | CN¥1.59 Billion ≈ $232.89 Million |
+39.12% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.40 Million |
+10.38% |
| 2019-12-31 | CN¥1.04 Billion ≈ $151.66 Million |
+10.25% |
| 2018-12-31 | CN¥940.07 Million ≈ $137.56 Million |
+4.44% |
| 2017-12-31 | CN¥900.07 Million ≈ $131.71 Million |
+4.26% |
| 2016-12-31 | CN¥863.31 Million ≈ $126.33 Million |
+10.87% |
| 2015-12-31 | CN¥778.65 Million ≈ $113.94 Million |
+110.34% |
| 2014-12-31 | CN¥370.18 Million ≈ $54.17 Million |
+22.43% |
| 2013-12-31 | CN¥302.37 Million ≈ $44.25 Million |
+21.25% |
| 2012-12-31 | CN¥249.37 Million ≈ $36.49 Million |
+28.94% |
| 2011-12-31 | CN¥193.41 Million ≈ $28.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Well Lead Med Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2256.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥687.17 Million | 39.01% |
| Other Components | CN¥1.07 Billion | 60.99% |
| Total Equity | CN¥1.76 Billion | 100.00% |
Well Lead Med Co Ltd Competitors by Market Cap
The table below lists competitors of Well Lead Med Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Leadman Biochemistry Co Ltd
SHE:300289
|
$472.86 Million |
|
Guangdong Huafeng New Energy Technology Co Ltd
SHE:002806
|
$472.92 Million |
|
CHC Resources Corp
TW:9930
|
$472.95 Million |
|
Medistim ASA
OL:MEDI
|
$473.02 Million |
|
Songz Automobile Air Conditioning Co Ltd
SHE:002454
|
$472.78 Million |
|
Cantor Equity Partners IV, Inc. Class A Ordinary Shares
NASDAQ:CEPF
|
$472.77 Million |
|
Xinhua Winshare Publishing and Media Co. Ltd
F:SXV
|
$472.75 Million |
|
Integra Resources Corp
V:ITR
|
$472.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Well Lead Med Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,884,975,721 to 1,761,687,120, a change of -123,288,601 (-6.5%).
- Net income of 76,327,701 contributed positively to equity growth.
- Dividend payments of 159,197,264 reduced retained earnings.
- Other factors decreased equity by 40,419,039.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥76.33 Million | +4.33% |
| Dividends Paid | CN¥159.20 Million | -9.04% |
| Other Changes | CN¥-40.42 Million | -2.29% |
| Total Change | CN¥- | -6.54% |
Book Value vs Market Value Analysis
This analysis compares Well Lead Med Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.18x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.99 | CN¥11.07 | x |
| 2012-12-31 | CN¥1.27 | CN¥11.07 | x |
| 2013-12-31 | CN¥1.55 | CN¥11.07 | x |
| 2014-12-31 | CN¥1.89 | CN¥11.07 | x |
| 2015-12-31 | CN¥3.15 | CN¥11.07 | x |
| 2016-12-31 | CN¥3.33 | CN¥11.07 | x |
| 2017-12-31 | CN¥3.40 | CN¥11.07 | x |
| 2018-12-31 | CN¥3.60 | CN¥11.07 | x |
| 2019-12-31 | CN¥3.99 | CN¥11.07 | x |
| 2020-12-31 | CN¥4.37 | CN¥11.07 | x |
| 2021-12-31 | CN¥6.10 | CN¥11.07 | x |
| 2022-12-31 | CN¥5.90 | CN¥11.07 | x |
| 2023-12-31 | CN¥6.23 | CN¥11.07 | x |
| 2024-12-31 | CN¥6.44 | CN¥11.07 | x |
| 2025-12-31 | CN¥6.04 | CN¥11.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Well Lead Med Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.68%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.62x
- Recent ROE (4.33%) is below the historical average (12.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 24.78% | 13.76% | 0.95x | 1.89x | CN¥28.58 Million |
| 2012 | 22.35% | 14.36% | 0.95x | 1.64x | CN¥30.73 Million |
| 2013 | 21.06% | 14.54% | 0.92x | 1.57x | CN¥33.39 Million |
| 2014 | 18.34% | 13.66% | 0.94x | 1.42x | CN¥30.85 Million |
| 2015 | 11.74% | 16.64% | 0.62x | 1.13x | CN¥13.50 Million |
| 2016 | 9.24% | 15.38% | 0.53x | 1.13x | CN¥-6.50 Million |
| 2017 | 7.24% | 10.25% | 0.62x | 1.13x | CN¥-24.64 Million |
| 2018 | 7.05% | 8.77% | 0.53x | 1.53x | CN¥-27.34 Million |
| 2019 | 11.79% | 12.19% | 0.68x | 1.42x | CN¥18.38 Million |
| 2020 | 13.50% | 13.54% | 0.76x | 1.31x | CN¥39.69 Million |
| 2021 | 6.72% | 9.48% | 0.52x | 1.35x | CN¥-51.75 Million |
| 2022 | 9.66% | 12.22% | 0.57x | 1.38x | CN¥-5.82 Million |
| 2023 | 10.59% | 13.87% | 0.53x | 1.43x | CN¥10.78 Million |
| 2024 | 11.64% | 14.54% | 0.53x | 1.51x | CN¥30.90 Million |
| 2025 | 4.33% | 4.68% | 0.57x | 1.62x | CN¥-99.84 Million |
Industry Comparison
This section compares Well Lead Med Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,285,039,921
- Average return on equity (ROE) among peers: 9.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Well Lead Med Co Ltd (603309) | CN¥1.79 Billion | 24.78% | 0.52x | $472.80 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.74 Billion | 2.80% | 1.18x | $498.13 Million |
| Blue Sail Medical Co Ltd (002382) | $1.18 Billion | 14.38% | 0.26x | $877.28 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $4.21 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $3.21 Billion | 3.44% | 0.58x | $792.30 Million |
| Guangzhou Improve Med Instrument (300030) | $1.00 Billion | 16.21% | 0.74x | $308.11 Million |
| QITIAN Technology Group Co Ltd (300061) | $2.47 Billion | -32.17% | 0.22x | $649.95 Million |
| Shanghai Tofflon Science Tech (300171) | $211.83 Million | 35.82% | 1.54x | $1.79 Billion |
| Truking Technology Ltd (300358) | $832.98 Million | 18.84% | 0.72x | $1.00 Billion |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.16 Billion | 15.98% | 0.55x | $689.10 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $290.70 Million | 15.03% | 0.44x | $1.29 Billion |
About Well Lead Med Co Ltd
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guid… Read more